Significant and Non-Significant Changes: The MDS-G012 Decision Framework

1. Key takeaways

MDS-G012 (Guidance on MDMA, Significant and Non-Significant Changes) is the dedicated Saudi guidance for judging post-licence changes. It connects directly with the Note in Part 3 of MDS-G011 V2.0 (MDS-G-011-V2/250707, 2025-07-07): any significant or non-significant change must be notified to the SFDA in accordance with MDS-G12. The judgement happens before the change is implemented, not as a retrospective report, and the outcome of the judgement decides whether the change follows a change application or a change notification, and which fee tier applies. For Chinese manufacturers already holding an MDMA, the real risk is not forgetting to report but implementing a significant change on the mistaken belief it is non-significant; once discovered at inspection, this simultaneously triggers a compliance problem under MDS-REQ 11 and a procedural problem under MDS-G012.

• Every change, significant or not, must be notified to the SFDA; no change is exempt from attention.
• The judgement tests the impact on safety and performance, not the size of the workload.
• Judgement is a gate before release: ECNs pass registration assessment before production.
• Fee tiers bind to change types; risk-class changes are charged at the full amount.
• Fee rates cited here are a practical estimate; official invoices prevail.

2. Legal basis

The change framework rests on MDS-G012 and the Note in MDS-G011 Part 3, supported by the licensing provisions of the implementing regulation and the parent law; the fee tiers are industry practice figures pending verification against official invoices.

3. Expert insights

1. The object of judgement is the change’s impact on safety and performance, not its size. In every regulatory system the line between significant and non-significant falls on whether the change may affect the safety and performance of the device, whether it alters the intended use, and whether it changes the risk class, not on the workload or cost of the change. Switching to a raw material supplier of equivalent qualification, changing the housing colour, or re-laying out the instructions for use may involve real work, but if safety and performance are unaffected it is usually non-significant; conversely, a seemingly small software logic adjustment that changes an alarm threshold can fall into the significant category. Chinese manufacturers’ engineering mindset assesses by volume of modification, while the registration mindset must assess by scope of impact; where the two conflict, scope of impact prevails. The judgement should be signed jointly by quality and registration; a unilateral conclusion from R&D is not acceptable.

2. Judgement before the event is a hard constraint of process design. The Note in Part 3 of MDS-G011 uses the wording that any significant or non-significant change must be notified under MDS-G12, pulling both categories of change into the notification obligation; the only difference is which procedure applies. This means no change exists that can be ignored. In practice the change judgement should be built as a gate: an engineering change order (ECN) must pass the registration judgement before release to production, and the conclusion and its basis are archived together. If judgement is placed after production, any conclusion of significant change immediately turns the handling of produced and shipped batches into a problem.

3. Fee tiers bind to change types, so budgets must be planned ahead. On the industry-standard fee calibre (a practical estimate, subject to official invoices): MDMA renewal is 5,000 Saudi riyals (SAR); adding a device, adding a model, a brand name change, and minor changes to the manufacturer name or address are each 5,000 SAR; label updates, IFU updates and advertising material updates are each 1,100 SAR; risk class changes and legal manufacturer name or address changes are charged at the full amount; all fees carry an additional 15% VAT and payment runs through SADAD. The implication for budgeting is direct: bundling several small changes into one submission differs markedly in cost from submitting them in batches, and because a risk class change is charged at the full amount, it is nearly equivalent to a fresh application, so the initial risk class determination must not be made casually. This connects directly to the classification logic in article 06.

The basis for risk class determination is covered at https://www.grzan.cn/regulations/saudi/sfda-risk-classification-abcd-06 , and the order of processing under the classification rules at https://www.grzan.cn/regulations/saudi/mds-g008-classification-rules-07 .

4. Practical recommendations

• Establish a change registration judgement gate in the quality system: no ECN is released until the registration judgement conclusion and signature are obtained.
• Build a change judgement checklist covering nine dimensions: intended use, design, materials, manufacturing process and site, sterilisation method, software version, label and IFU, legal manufacturer name and address, and risk class.
• Archive the judgement conclusion and basis, including the judger, the date and the MDS-G012 provisions relied on (current version per the website download).
• For changes that may touch the risk class, run a classification review first to avoid the full-amount fee tier (rates are a practical estimate).
• Batch minor label and IFU changes into combined schedules to reduce the number of submissions and the fees paid.
• Have the AR submit the change notification or application through the GHAD portal and retain the acceptance receipt.
• Release production and shipment only after the change is approved; do first and report later is prohibited.
• After a change takes effect, update Saudi-DI and the internal PMS ledger in sync to keep the data consistent.

5. Verification checklist

• □ The current version of MDS-G012 has been downloaded from the SFDA website and its version date checked (a practical estimate)
• □ The change judgement gate is written into the quality system procedure documents
• □ The nine-dimension change judgement checklist has been issued
• □ The archiving template for judgement conclusions and basis is ready
• □ The budget tier for risk class changes has been assessed
• □ Label and IFU changes have been combined into one schedule
• □ The AR has submitted through GHAD and retained the acceptance receipt
• □ Saudi-DI and the PMS ledger have been updated in sync after the change took effect
• □ Fee rates follow the invoices of the GHAD or SFDA billing system (a practical estimate)

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team manages adverse event reporting and recall coordination with the SFDA National Center, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com